Roche Holding AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RHHBF | NVS | AZN | GILD | BMY | AMGN | |
|---|---|---|---|---|---|---|
| Market cap | 365.29B | 286.29B | 256.54B | 193.67B | 122.05B | 233.82B |
| P/E (TTM) | 23.7 | 22.8 | 23.8 | — | 13.2 | 26.9 |
| Forward P/E | 30.9 | 15.4 | 14.6 | 15.7 | 9.0 | 17.7 |
| Price/book | 9.3 | 6.9 | 5.1 | 16.4 | 5.5 | 20.0 |
| Dividend yield | 2.71% | 3.15% | 1.94% | 2.10% | 4.22% | 2.33% |
| 1-year change | +25.17% | +14.29% | −1.39% | +26.87% | +37.07% | +42.58% |
| Today | 0.00% | +0.16% | −0.76% | −0.75% | −1.35% | −0.35% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All RHHBF news ›FDA clears Roche's Enspryng for thyroid eye disease
Roche has claimed US approval for IL-6 receptor antagonist Enspryng in a second indication – thyroid eye disease (TED) – that furthers its ambition to grow the drug into a blockbuster product. Enspryng (satralizumab) has been approved for…
Cardinal Roche Rules Out Any Return to Freedom for the Traditional Mass
How far will Rome go to eliminate the traditional Mass? Cardinal Roche's statements leave little doubt about the determination of its opponents. “He will not change Traditionis Custodes. He will not revert to Summorum Pontificum.” For…
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous TED Treatment
The FDA first approved the drug for neuromyelitis optica spectrum disorder in 2020. Editor’s Take: Not only is this the first subcutaneous treatment for TED, but it also provides an important administration option. Roche announced the U.S.…
Roche reports phase 3 data on steroid-free therapy for UME management
Next year is gearing up for anticipated regulatory movement in the uveitic macular edema (UME) space. Why, you ask? One word: vamibikart. Following Roche’s latest phase 3 data readout during the American Academy of Ophthalmology (AAO) 2026…
FDA approves Roche’s Enspryng for TED - The Pharma Letter
FDA approves Roche’s Enspryng for TED The Pharma Letter
“This management is not suited to cycling” – Nicolas Roche tears into Picnic PostNL amid bombshell fear-culture allegations
CyclingUpToDate.com “This management is not suited to cycling” – Nicolas Roche tears into Picnic PostNL amid bombshell fear-culture allegations “My experience became a problem for management” “You do what you are told” “We had just won!”…
Former Brothers Marketplace space vacant after five years as Roche Bros. retains lease
The former Brothers Marketplace space at The Merc at 1 Moody St. has remained vacant since Roche Bros. Supermarkets closed the store in 2021. Roche Bros. continues to hold the lease, but the future of the 12,000 square foot space is…
Roche Secures Global Rights to Rona Therapeutics’ RNAi Obesity Candidate in Deal Worth Up to $1.16 Billion
15 October 2026 | Thursday | News - Rona Therapeutics announced it has granted Roche an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's…
Roche breast cancer drug Itovebi turned down by NICE
Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a decision the company has described as "devastating." In final draft guidance published this morning, NICE said that it…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com20
-
tradingview.com7
-
openpr.com6
-
biospace.com4
-
firstwordpharma.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.